Literature DB >> 22154511

Role for Class I histone deacetylases in multidrug resistance.

Yichun Xu1, Zijing Jiang, Peihao Yin, Qi Li, Jianwen Liu.   

Abstract

Recent reports have showed that histone deacetylase (HDAC) inhibitor resulted in multidrug resistance (MDR) to other chemotherapeutic agents. However, the molecular mechanisms of Class I HDACs on MDR regulation are poorly understood. In this study, HDAC1 and HDAC2 acted as enhancers to intensify the chemosensitivities of anti-cancer drugs via reducing the expression levels of P-gp, MRP1 and MRP2. Furthermore, the dissociation of HDAC1 and HDAC2 led to transcriptional regulation of P-gp expression via the recruitment of p300, PCAF and NF-Y to the P-gp promoter region, which subsequently increased the level of the active gene marker, hyperacetylated histone H3. In parallel, selective inhibition of HDAC1 and HDAC2 induced the recruitment of p300, PCAF, NF-Y via acetylation of Sp1. Thus, our findings showed HDAC1 and 2 regulated P-gp expression through dynamic changes in chromatin structure and transcription factor association within the promoter region. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154511     DOI: 10.1016/j.yexcr.2011.11.010

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  14 in total

1.  3B, a novel of photosensitizer, exhibited anti-tumor effects via mitochondrial apoptosis pathway in MCF-7 human breast carcinoma cells.

Authors:  Kecheng Lei; Shaoying Tan; Wenpei Du; Yichun Xu; Shengchao Lin; Yuanhong Zheng; Fangyuan Zou; Yufang Xu; Jianwen Liu
Journal:  Tumour Biol       Date:  2015-02-27

2.  Histone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1.

Authors:  Prerna Kumar; Satyabha Tripathi; Kailash N Pandey
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

Review 3.  Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?

Authors:  D Dolfini; R Mantovani
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

4.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

Review 5.  Epigenomic regulation of oncogenesis by chromatin remodeling.

Authors:  R Kumar; D-Q Li; S Müller; S Knapp
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

6.  Marked differences in the effect of antiepileptic and cytostatic drugs on the functionality of P-glycoprotein in human and rat brain capillary endothelial cell lines.

Authors:  Dana Alms; Maren Fedrowitz; Kerstin Römermann; Andreas Noack; Wolfgang Löscher
Journal:  Pharm Res       Date:  2014-01-30       Impact factor: 4.200

7.  HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review).

Authors:  Xuan Ni; Li Li; Guoyu Pan
Journal:  Oncol Lett       Date:  2014-11-19       Impact factor: 2.967

8.  Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms.

Authors:  L Wang; H Li; Y Ren; S Zou; W Fang; X Jiang; L Jia; M Li; X Liu; X Yuan; G Chen; J Yang; C Wu
Journal:  Cell Death Dis       Date:  2016-01-21       Impact factor: 8.469

9.  Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.

Authors:  Nikolai V Litviakov; Nadezhda V Cherdyntseva; Matvey M Tsyganov; Elena M Slonimskaya; Marina K Ibragimova; Polina V Kazantseva; Julia Kzhyshkowska; Eugeniy L Choinzonov
Journal:  Oncotarget       Date:  2016-02-16

10.  Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs.

Authors:  Hyuna Kim; Youngmi Kim; Hyeonjung Goh; Dooil Jeoung
Journal:  Mol Cells       Date:  2016-02-16       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.